Print

Peregrine Pharmaceuticals, Inc. (PPHM) to Report Second Quarter Fiscal Year 2013 Financial Results After Market Close on December 10, 2012  
12/4/2012 10:02:36 AM

TUSTIN, CA--(Marketwire - December 03, 2012) -

Peregrine Pharmaceuticals (NASDAQ: PPHM), a clinical-stage biopharmaceutical company developing first-in-class monoclonal antibodies focused on the treatment and diagnosis of cancer, today announced that it will report financial results for the second quarter of the fiscal year 2013 on December 10, 2012 after market and will host a conference call and webcast at 1:30 PM PT (4:30 PM ET). Peregrine's senior management will discuss financial results for the second quarter of fiscal year ended October 31, 2012 and will review progress of its clinical development programs.

To listen to the live webcast, or access the archived webcast, please visit: http://ir.peregrineinc.com/events.cfm.

To listen to the conference call, please dial (877) 312-5443 or (253) 237-1126 and request the Peregrine Pharmaceuticals call. A replay of the call will be available starting approximately two hours after the conclusion of the call through December 24, 2012 by calling (855) 859-2056, or (404) 537-3406 and using passcode 75630640.

About Peregrine Pharmaceuticals
Peregrine Pharmaceuticals, Inc. is a biopharmaceutical company with a portfolio of innovative monoclonal antibodies in clinical trials focused on the treatment and diagnosis of cancer. The company is pursuing multiple clinical programs in cancer with its lead product candidate bavituximab and novel brain cancer agent Cotara®. Peregrine also has in-house cGMP manufacturing capabilities through its wholly-owned subsidiary Avid Bioservices, Inc. (www.avidbio.com), which provides development and biomanufacturing services for both Peregrine and outside customers. Additional information about Peregrine can be found at www.peregrineinc.com.


Contact:
Christopher Keenan or Jay Carlson
Peregrine Pharmaceuticals, Inc.
(800) 987-8256
info@peregrineinc.com

Digg this    Bookmark with del.icio.us    Add to Newsvine

Technorati:


//-->